Valuation: Cerus Corporation

Market Cap 510M 444M 420M 382M 713M 48.83B 717M 5.01B 1.94B 24.82B 1.92B 1.87B 79.44B P/E 2026 *
-72.3x
P/E 2027 * -253x
Enterprise Value 515M 448M 424M 386M 720M 49.31B 724M 5.06B 1.95B 25.06B 1.93B 1.89B 80.22B EV / Sales 2026 *
2.07x
EV / Sales 2027 * 1.83x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day+3.36%
1 week+5.37%
Current month-1.81%
1 month-12.72%
3 months+0.86%
6 months+44.01%
Current year+25.83%
1 week 2.45
Extreme 2.45
2.63
1 month 2.45
Extreme 2.45
3
Current year 1.62
Extreme 1.62
3.47
1 year 1.24
Extreme 1.24
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 A Sell

General Counsel

-30,000 0.0150%
7/16/26 A Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 A Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
+3.36%+5.37%+110.75%+62.01% 510M
-1.13%+4.35%-25.24%-3.91% 109B
-0.62%+0.98%-24.47%-1.24% 11.79B
-0.96%-4.64%+97.89%+115.11% 9.64B
-0.05%-2.23%-53.87%-71.50% 3.99B
+0.03%-3.85%-29.59%+21.70% 2.33B
+1.73%+8.65%-7.49%-64.77% 2.1B
+0.95%-2.05% - - 1.82B
-0.23%-2.00%-22.54%-30.30% 1.52B
Average +0.33%+0.95%+5.68%+3.39% 15.88B
Weighted average by Cap. -0.95%+2.31%-16.86%+2.00%

Financials

2026 *2027 *
Net sales 249M 217M 205M 187M 348M 23.85B 350M 2.45B 946M 12.12B 936M 915M 38.8B 272M 236M 224M 203M 380M 26B 382M 2.67B 1.03B 13.22B 1.02B 997M 42.31B
Net income -8.77M -7.64M -7.23M -6.57M -12.27M -840M -12.33M -86.08M -33.28M -427M -32.93M -32.2M -1.37B -1.67M -1.45M -1.37M -1.25M -2.33M -160M -2.34M -16.36M -6.33M -81.12M -6.26M -6.12M -260M
Net Debt 5M 4.36M 4.12M 3.74M 7M 479M 7.03M 49.09M 18.98M 243M 18.78M 18.37M 779M -13M -11.32M -10.72M -9.74M -18.19M -1.25B -18.28M -128M -49.36M -633M -48.84M -47.75M -2.03B
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
17/09/26 $2.600 +2.77% 1,743,893
16/09/26 $2.530 +1.20% 1,455,624
15/09/26 $2.500 -1.96% 1,019,084
14/09/26 $2.550 +2.41% 1,349,636
11/09/26 $2.490 +1.22% 1,545,740
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.530USD
Average target price
5.125USD
Spread / Average Target
+102.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!